Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If you need an accessible version of this item please contact JSTOR User Support

Treatment of Urinary Tract Infections with Cefotaxime: Noncomparative and Prospective Comparative Trials

Paul O. Madsen
Reviews of Infectious Diseases
Vol. 4, Supplement. Current Status of Cefotaxime Sodium: A New Cephalosporin (Sep. - Oct., 1982), pp. S416-S420
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4452899
Page Count: 5
  • Get Access
  • Download ($42.00)
  • Cite this Item
If you need an accessible version of this item please contact JSTOR User Support
Treatment of Urinary Tract Infections with Cefotaxime: Noncomparative and Prospective Comparative Trials
Preview not available

Abstract

Three studies evaluated the efficacy of cefotaxime for the treatment of urinary tract infections. An open, multicenter, noncomparative trial included 477 patients who received a usual dose of 2 g of intravenous or intramuscular cefotaxime daily for five to 10 days. The maximal daily dosage in severe cases was 12 g. Pathogens included Escherichia coli and species of Citrobacter, Pseudomonas, Klebsiella, Enterobacter, Serratia, Morganella, Providencia, and Proteus. Of all the causative organisms, 83.6% were eradicated in the 271 patients who could be evaluated. The other two studies were prospective, randomized comparisons of cefotaxime (392 patients) with cefazolin (250 patients) for the treatment of urinary tract infections caused by microorganisms susceptible to both antibiotics. The treatment schedule was the same as that in the first study. Results of these two prospective studies were pooled. Cefotaxime eradicated 90% of all pathogens, and cefazolin eradicated 72%. Cefotaxime was significantly more effective (P <0.01) than cefazolin in eradicating E. coli and Proteus mirabilis. A satisfactory clinical response was obtained in 98.1% of patients given cefotaxime and in 87.6% of those given cefazolin (P <0.01).

Page Thumbnails

  • Thumbnail: Page 
S416
    S416
  • Thumbnail: Page 
S417
    S417
  • Thumbnail: Page 
S418
    S418
  • Thumbnail: Page 
S419
    S419
  • Thumbnail: Page 
S420
    S420